

PCT

EP 0724428  
WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 9/00, 9/16	A1	(11) International Publication Number: WO 95/11007 (43) International Publication Date: 27 April 1995 (27.04.95)
(21) International Application Number: PCT/US94/11893 (22) International Filing Date: 18 October 1994 (18.10.94)  (30) Priority Data: 138,345 18 October 1993 (18.10.93) US 200,636 23 February 1994 (23.02.94) US  (71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US/US); 77 Massachusetts Avenue, Cambridge, MA 02139 (US).  (72) Inventors: CIMMA, Linda, G.; 2101 Massachusetts Avenue, Lexington, MA 02173 (US). CIMMA, Michael, J.; 2101 Massachusetts Avenue, Lexington, MA 02173 (US).  (74) Agent: PABST, Patrea, L.; Arnall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3400 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PREPARATION OF MEDICAL DEVICES BY SOLID FREE-FORM FABRICATION METHODS		
(57) Abstract		
Solid free-form techniques for making medical devices for controlled release of bioactive agent and implantation and growth of cells are described using computer aided design. Examples of SFF methods include stereo-lithography (SLA), selective laser sintering (SLS), ballistic particle manufacturing (BPM), fusion deposition modeling (FDM), and three dimensional printing (3DP). The macrostructure and porosity of the device can be manipulated by controlling printing parameters. Most importantly, these features can be designed and tailored using computer assisted design (CAD) for individual patients to optimize therapy.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgian	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**PREPARATION OF MEDICAL DEVICES BY  
SOLID FREE-FORM FABRICATION METHODS**

**Background of the Invention**

The present invention is generally in the area  
5 of methods for formulation of medical devices, in particular using computer aided design in combination with solid free-form fabrication technology.

Many drug regimes require hospitalization or  
10 repeated visits because they must be carefully dosed for individual patients or are too complicated for patients to administer themselves. Significant cost savings could be realized if hospital stay and visits were reduced by use of  
15 drug delivery devices that accurately deliver drugs at predefined rates for individual patients. Many other drugs which are self-administered have low efficacy because patient compliance is low, even when drugs are supposed to be taken on a simple  
20 dosage regime such as once a day.

A number of approaches have been proposed as a means for controlled drug delivery which avoids some of the problems with patient compliance. In most of these cases, this has been achieved by  
25 encapsulation of the drug in a polymeric material which releases drug by diffusion, degradation, or a combination of diffusion and degradation, over time. Methods include solvent casting, solvent evaporation, solvent extraction, spray drying, and  
30 compression molding. The resulting devices are in the form of tablets, slabs, microparticles, microspheres, and microcapsules. Multiphase release is achieved by encapsulating drug within multiple layers having different release profiles.

35 One of the problems with the current technology for drug manufacture is the lack of

precision and resulting lack of quality control. This in turn causes a lack of precision in the release rates of the encapsulated drug. It also limits the types of multiphasic release to one or  
5 two "bursts".

Construction of drug delivery devices which could release drugs according to complex prescribed temporal patterns would increase patient compliance by reducing the number of times a patient must  
10 administer the drug. No such methods have been reported at this time, however.

Similarly, a number of approaches have been proposed for construction of synthetic polymeric matrices for growth of cells *in vivo*, for example,  
15 to replace organ function or to provide structural support, i.e., new bone. Such methods have been reported by Vacanti, et al., Arch. Surg. 123, 545-549 (1988), U.S. Patent No. 4,060,081 to Yannas, et al., U.S. Patent No. 4,485,097 to Bell, and U.S.  
20 Patent No. 4,520,821 to Schmidt, et al. In general, however, the methods used by Vacanti, et al., and Schmidt, et al., involved selecting and adapting existing compositions for implantation and seeding with cells, while the methods of Yannas and  
25 Bell were used to produce very specific structures.

Various materials are used to fabricate inorganic or inorganic/polymer matrices for bone regeneration. These include the coralline replaniform hydroxyapatite, which is essentially an  
30 adapted coral as described by Martin, R.B., et al., "Bone ingrowth and mechanical properties of coralline hydroxyapatite one year after implantation," Biomaterials, 14:341-348 (1993), and devices which incorporate a cellular component,  
35 as described by U.S. Patents 4,620,327, 4,609,551, 5,226,914 and 5,197,985 to Arnold Caplan. Composite materials have also been described;

however, they have been used primarily for fixation devices, and not bone ingrowth. See, for example, Boeree, N.R., et al., "Development of a degradable composite for orthopedic use: mechanical evaluation of an hydroxyapatite-polyhydroxybutyrate composite material," Biomaterials, 14:793-796 (1993).

Strategies for regenerating tissue are being developed in response to a range of clinical needs, including replacement of damaged or genetically absent metabolic function from tissues such as liver, pancreas and pituitary tissue, and repair or restructuring of damaged or malformed connective tissues such as bone, cartilage and skin. Unlike blood or bone marrow tissues which can be regenerated by intravenous injection of cells, regeneration of most tissues requires a template to guide their growth.

New therapies for tissue regeneration include approaches in which cells are transplanted into a patient along with a device, and approaches in which a device is implanted next to normal tissue and guides the growth of that tissue into a new region. An example of the latter is a bone regeneration device placed into a fracture site, which guides growth of bone tissue into the fracture.

Tissue regeneration devices must be porous with interconnected pores to allow cell and tissue penetration; however, factors such as pore size, shape and tortuosity can all affect tissue ingrowth but are difficult to control using standard processing techniques. None of the prior art methods, however, can be used to construct specific structures from biocompatible synthetic polymers, having defined pore sizes, particularly different pore sizes within the same structure, especially in discrete regions of the structure.

It would be advantageous to construct specific structures from biocompatible synthetic or natural polymers, inorganic materials, or composites of inorganic materials with polymers, where the

5 resulting structure has defined pore sizes, shapes and orientations, particularly different pore sizes and orientations within the same device, with more than one surface chemistry or texture at different specified sites within the device.

10 It is therefore an object of the present invention to provide methods and compositions made according to complex temporal patterns for use in drug delivery and tissue regeneration.

It is an object of the present invention to

15 provide methods and compositions for making complex medical devices of erodible or erodible and non-erodible materials which can be used as drug delivery devices or for seeding of cells.

It is a further object of the present

20 invention to provide methods that operate with high precision and reproducibility to produce medical devices.

It is a still further object of the present invention to provide bioerodible devices which are

25 structurally stable during erosion.

It is another object of the present invention to provide methods and compositions for making complex medical devices of bioerodible or non-bioerodible materials or composites for either cell

30 transplantation or matrix-guided tissue regeneration.

It is a further object of the present invention to provide methods that operate with high precision and reproducibility to produce medical

35 devices.

It is a still further object of the present invention to produce devices which can selectively

encourage the growth of one tissue type over another at specific sites within the matrix by virtue of control of surface chemistry and texture or growth factor release at that region of the matrix.

### Summary of the Invention

Solid free-form fabrication (SFF) methods are used to manufacture devices for controlled release of bioactive agents and for seeding and  
10 implantation of cells to form organ and structural components. These methods can be adapted for use with a variety of different materials to create structures with defined compositions, strengths, and densities, through the use of computer aided  
15 design (CAD). Examples of SFF methods include stereo-lithography (SLA), selective laser sintering (SLS), ballistic particle manufacturing (BPM), fusion deposition modeling (FDM), and three dimensional printing (3DP). In a preferred  
20 embodiment, 3DP is used to precisely position bioactive agent(s) within a release matrix to control the rate of release and allow either a pulsed or constant release profile. In another preferred embodiment, 3DP is used to create a  
25 porous bioerodible matrix having interconnected pores or channels, typically between 0.15 and 0.5 mm, which are separated by walls approximately 30 to 100 microns thick, which have an average pore size of approximately 5 to 40 microns.

30 The macrostructure and porosity of the device can be manipulated by controlling printing parameters, the type of polymer and particle size, as well as the solvent and/or binder. Porosity of the matrix walls, as well as the matrix *per se*, can  
35 be manipulated using SFF methods, especially 3DP.

Structural elements that maintain the integrity of the devices during erosion can also be incorporated so that more linear release of incorporated material is obtained. For example, to provide support, the walls of the device can be filled with resorbable inorganic material, which can further provide a source of mineral for the regenerating tissue. Most importantly, these features can be designed and tailored using computer assisted design (CAD) for individual patients to optimize drug therapy or cell type.

#### Brief Description of the Drawings

Figures 1A and 1B are perspective and cross-sectional views, respectively, of polymeric bioactive agent delivery devices made according to the method described herein.

Figures 2A, 2B, and 2C are schematic diagrams of a tissue engineering device: the macroscopic device having a porous internal structure (2A); an expanded excerpt of 2A showing three dimensional position of large features including channels that are oriented transversely and longitudinally, and dispersed drug and growth factors (2B); and an expanded excerpt of 2B showing the microstructure, including porous or solid walls (2C).

#### Detailed Description of the Invention

Solid free-form fabrication methods offer several unique opportunities for the construction of medical devices for the delivery of bioactive agents or tissue engineering. Devices for bioactive agent delivery can be constructed with specified bioactive agent composition gradient and



structure so that the dosage regimes can be much more complex than currently practiced and tailored for the needs of individual patients. Devices for tissue regeneration can be constructed to fit the individual patient, individual cell type or organ structure. SFF methods can be used to selectively control composition within the build plane by varying the composition of printed material. This means that unconventional microstructures, such as those with complicated porous networks or unusual composition gradients, can be designed at a CAD terminal and built through an SFF process such as 3DP. Complex resorbable or erodible medical devices can also be built which incorporate structural elements to insure the structural integrity of the device during erosion.

Examples of useful SFF processes include:

Three Dimensional Printing (3DP).

3DP is described by Sachs, et al., "CAD-Casting: Direct Fabrication of Ceramic Shells and Cores by Three Dimensional Printing" Manufacturing Review 5(2), 117-126 (1992) and U.S. Patent No. 5,204,055 to Sachs, et al., the teachings of which are incorporated herein. Suitable devices include both those with a continuous jet stream print head and a drop-on-demand stream print head. A high speed printer of the continuous type, for example, is the Dijit printer made and sold by Diconix, Inc., of Dayton, Ohio, which has a line printing bar containing approximately 1500 jets which can deliver up to 60 million droplets per second in a continuous fashion and can print at speeds up to 900 feet per minute. Both raster and vector apparatuses can be used. A raster apparatus is where the printhead goes back and forth across the bed with the jet turning on and off. This can have problems when the material is likely to clog the

jet upon settling. A vector apparatus is similar to an x-y printer. Although potentially slower, the vector printer may yield a more uniform finish.

- 3DP is used to create a solid object by ink-jet printing a binder into selected areas of sequentially deposited layers of powder. Each layer is created by spreading a thin layer of powder over the surface of a powder bed. The powder bed is supported by a piston which descends upon powder spreading and printing of each layer (or, conversely, the ink jets and spreader are raised after printing of each layer and the bed remains stationary). Instructions for each layer are derived directly from a computer-aided design (CAD) representation of the component. The area to be printed is obtained by computing the area of intersection between the desired plane and the CAD representation of the object. The individual sliced segments or layers are joined to form the three dimensional structure. The unbound powder supports temporarily unconnected portions of the component as the structure is built but is removed after completion of printing.

- As shown in U.S. Patent No. 5,204,055, the 3DP apparatus includes a powder dispersion head which is driven reciprocally in a shuttle motion along the length of the powder bed. A linear stepping motor assembly is used to move the powder distribution head and the binder deposition head. The powdered material is dispensed in a confined region as the dispensing head is moved in discrete steps along the mold length to form a relatively loose layer having a typical thickness of about 100 to 200 microns, for example. An ink-jet print head having a plurality of ink-jet dispensers is also driven by the stepping motor assembly in the same reciprocal manner so as to follow the motion of the

powder head and to selectively produce jets of a liquid binder material at selected regions which represent the walls of each cavity, thereby causing the powdered material at such regions to become

5 bonded. The binder jets are dispensed along a line of the printhead which is moved in substantially the same manner as the dispensing head. Typical binder droplet sizes are about 15-50 microns. The powder/binder layer forming process is repeated so

10 as to build up the device layer by layer.

While the layers become hardened or at least partially hardened as each of the layers is laid down, once the desired final part configuration is achieved and the layering process is complete, in

15 some applications it may be desirable that the form and its contents be heated or cured at a suitably selected temperature to further promote binding of the powder particles. In either case, whether or not further curing is required, the loose, unbonded

20 powder particles are removed using a suitable technique, such as ultrasonic cleaning, to leave a finished device.

Construction of a 3DP component can be viewed as the knitting together of structural elements

25 that result from printing individual binder droplets into a powder bed. These elements are called microstructural primitives. The dimensions of the primitives determine the length scale over which the microstructure can be changed. Thus, the

30 smallest region over which the concentration of bioactive agent can be varied has dimensions near that of individual droplet primitives. Droplet primitives have dimensions that are very similar to the width of line primitives formed by consecutive

35 printing of droplets along a single line in the powder bed. The dimensions of the line primitive depend on the powder and the amount of binder

printed per unit line length. A line primitive of 500  $\mu\text{m}$  width is produced if an ink jet depositing 1.1 cc/min of methylene chloride is made to travel at 8"/sec over the surface of a PLC powder bed with 5 45-75  $\mu\text{m}$  particle size. Higher print head velocities and smaller particle size produce finer lines. The dimensions of the primitive seem to scale with that calculated on the assumption that the liquid binder or solvent needs to fill the 10 pores of the region in the powder which forms the primitive.

Finer feature size is also achieved by printing polymer solutions rather than pure solvents. For example, a 10 wt. % PLC solution in 15 chloroform produces 200  $\mu\text{m}$  lines under the same conditions as above. The higher solution viscosity prevents slows the migration of solvent away from the center of the primitive.

The solvent drying rate is an important 20 variable in the production of polymer parts by 3DP. Very rapid drying of the solvent tends to cause warping of the printed component. Much, if not all, of the warping can be eliminated by choosing a solvent with a low vapor pressure. Thus, PCL parts 25 prepared by printing chloroform have nearly undetectable amounts of warpage, while large parts made with methylene chloride exhibit significant warpage. It has been found that it is often convenient to combine solvents to achieve minimal 30 warping and adequate bonding between the particles. Thus, an aggressive solvent can be mixed in small proportions with a solvent with lower vapor pressure.

There are two principle methods for 35 incorporation of bioactive agent. In the first method, a layer of dispersed fine polymer powder is selectively bound by ink-jet printing a solvent

onto the polymer particles which dissolves the polymer. This process is repeated for subsequent layers to build up the cylinder, printing directly on top of the preceding layer, until the desired shape is achieved. If it is desired to design a constant rate release matrix, the drug is dissolved or dispersed (e.g., micellar) in the solvent, yielding drug dispersed evenly through the matrix. The printing process for this case would then be continued layer by layer until the desired shape was obtained.

In the second method, devices for pulsed release of drugs are prepared by constructing drug-rich regions within the polymer matrix. In this case, multiple printheads are used to deposit drug containing solvent in selected regions of the powder bed. The remaining volume of the desired device is bound with pure solvent deposited by a separate printhead. The printing process is repeated layer by layer to yield a device which gives a pulsed release of drug. For example, a cylindrical device could contain a cylindrical annulus region which is enriched with a drug.

Significant amounts of matter can be deposited in selective regions of a component on a 100  $\mu\text{m}$  scale by printing solid dispersions or solid precursors through the ink-jet print heads with hundreds of jets can be incorporated into the process. The large number of individually controlled jets make high rate 3DP construction possible.

Stereo-lithography (SLA) and selective laser sintering (SLS).

SFF methods are particularly useful for their ability to control composition and microstructure on a small scale for the construction of these medical devices. The SFF methods, in addition to

3DP, that can be utilized to some degree as described herein are stereo-lithography (SLA), selective laser sintering (SLS), ballistic particle manufacturing (BPM), and fusion deposition modeling (FDM).

5 Stereolithography is based on the use of a focused ultra-violet (UV) laser which is vector scanned over the top of a bath of a photopolymerizable liquid polymer material. The UV  
10 laser causes the bath to polymerize where the laser beam strikes the surface of the bath, resulting in the creation of a first solid plastic layer at and just below the surface. The solid layer is then lowered into the bath and the laser generated  
15 polymerization process is repeated for the generation of the next layer, and so on, until a plurality of superimposed layers forming the desired device is obtained. The most recently created layer in each case is always lowered to a  
20 position for the creation of the next layer slightly below the surface of the liquid bath. A system for stereolithography is made and sold by 3D Systems, Inc., of Valencia, CA, which is readily adaptable for use with biocompatible polymeric  
25 materials.

SLS also uses a focused laser beam, but to sinter areas of a loosely compacted plastic powder, the powder being applied layer by layer. In this method, a thin layer of powder is spread evenly  
30 onto a flat surface with a roller mechanism. The powder is then raster-scanned with a high-power laser beam. The powder material that is struck by the laser beam is fused, while the other areas of powder remain dissociated. Successive layers of  
35 powder are deposited and raster-scanned, one on top of another, until an entire part is complete. Each layer is sintered deeply enough to bond it to the

preceding layer. A suitable system adaptable for use in making medical devices is available from DTM Corporation of Austin, TX.

- SLA and SLS are similar in that matter is
- 5 laminated to make three dimensional shapes. The two dimensional profile of each laminate is specified by different methods in the two techniques. Selective photopolymerization of a thin layer of polymer precursor is performed during
- 10 SLA to define the shape of each layer and bond the layer to previous layers. SLS selectively sinters layers of powder using a laser to define the shape of each layer and to bond to the previous layer. Use of these methods to control composition is
- 15 limited to one dimensional control since one can only vary the composition of each layer. Nonetheless, these methods can be useful for construction of drug delivery and tissue matrix devices where one dimensional compositional control
- 20 is all that is desired or where only variation in porosity is desired. Controlled porosity can be built using SLA and SLS simply by specifying the laser path over the layer surface to include only those regions which are to remain in the device.
- 25 However, SLA and SLS pose significant material constraints for the construction of drug delivery devices and tissue matrix preforms. SLA is limited to use with a photopolymerizable precursor that yields a biocompatible solid, such as UV or visible
- 30 light curable acrylic systems used for bioadhesives, or a photo-curable material such as polyethylene oxide (PEO) precursors terminated with photo-crosslinking end groups. This process can be performed in the presence of sensitive
- 35 biomolecules. Thus, structures can be built that incorporate drugs. Secondly, variation of the laser intensity or traversal speed can be used to

- vary the cross-link density within a layer so that the properties of the material can be varied from position to position with the part. SLS has the disadvantage that incorporation of sensitive biomolecules is difficult because of the need to locally heat the powder layer so as to sinter it. Nonetheless, highly porous structures can be built with low melting polymers, such as PEO powder. Variation of the laser intensity or traversal speed controls the degree of local densification. Thus, regions where the laser intensity is high or the traversal speed is low will have higher density.

Ballistic particle manufacturing (BPM) and Fusion deposition modeling (FDM)

- BPM uses an ink-jet printing apparatus wherein an ink-jet stream of liquid polymer or polymer composite material is used to create three-dimensional objects under computer control, similar to the way an ink-jet printer produces two-dimensional graphic printing. The device is formed by printing successive cross-sections, one layer after another, to a target using a cold welding or rapid solidification technique, which causes bonding between the particles and the successive layers. This approach as applied to metal or metal composites has been proposed by Automated Dynamic Corporation of Troy, NY.

- FDM employs an x-y plotter with a z motion to position an extrudable filament formed of a polymeric material, rendered fluid by heat or the presence of a solvent. A suitable system is available from Stratasys, Incorporated of Minneapolis, MN.

- BPM, FDM and 3DP are related in the sense that all three approaches deposit matter in small areas. Thus, they offer the advantage that local composition can be specified and constructed for



any desired three dimensional profile. The composition control is only limited by the resolution of the particular apparatus used for construction. FDM builds structures by extruding a fine filament of plastically deformable material through a small nozzle. The nozzle is directed over the built surface by appropriate x, y and z motion control so as to yield the desired three dimensional structure. Similarly, BPM involves motion control of an ink jet print head to deposit matter in the form of small droplets. Appropriate control of where the droplets are printed permits the construction of a desired three dimensional shape. 3DP uses two sources of material: the material that makes up the porous layer and the material that is printed.

Local composition control using FDM and BPM requires the application of multiple printing or extrusion tools. A similar approach can be followed with 3DP by using multiple print-heads. Alternatively, multiple droplets may be printed into the same location when using 3DP to increase the local composition of the species contained in the printed solution.

Porosity control using BPM and FDM can be accomplished using procedures similar to those which can be practiced using 3DP, as described below.

#### Selection of Polymers

Depending on the processing method, the polymer forming the matrix may be in solution, as in the case of SLA, or in particle form, as in the case of SLS, BPM, FDM, and 3DP. In the first method, the polymer must be photopolymerizable. In the latter methods, the polymer is preferably in particulate form and is solidified by application of heat, solvent, or binder (adhesive). In the

case of SLS and FDM, it is preferable to select polymers having relatively low melting points, to avoid exposing incorporated bioactive agent to elevated temperatures.

- 5 In the case of 3DP, a polymeric material, preferably in particulate form, or as a porous sheet, is applied to a solid platform on a movable piston for solidification and/or incorporation of bioactive agent. A roller evenly spreads the
- 10 particles over the platform bed. Solvent and/or binder and bioactive agent is then selectively printed onto the polymer particles. After each layer is "printed", the piston lowers the polymeric material so that the process can be repeated to
- 15 form the next layer.

The particles can be of any shape, including fibrous or rod shaped, although a more spherical particle will typically flow more smoothly. The particles are preferably in the range of ten

20 microns or greater in diameter, although smaller particles can be used if spread in a liquid medium and allowed to dry in between printings.

- A number of materials are commonly used to form a matrix for bioactive agent delivery. Unless
- 25 otherwise specified, the term "polymer" will be used to include any of the materials used to form the bioactive agent matrix, including polymers and monomers which can be polymerized or adhered to form an integral unit. In a preferred embodiment
- 30 the particles are formed of a polymer, such as a synthetic thermoplastic polymer, for example, ethylene vinyl acetate, poly(anhydrides), polyorthoesters, polymers of lactic acid and glycolic acid and other  $\alpha$  hydroxy acids, and
- 35 polyphosphazenes, a protein polymer, for example, albumin or collagen, or a polysaccharide containing sugar units such as lactose. The polymer can be

non-biodegradable or biodegradable, typically via hydrolysis or enzymatic cleavage. Non-polymeric materials can also be used to form the matrix and are included within the term "polymer" unless otherwise specified. Examples include organic and inorganic materials such as hydroxyapatite, calcium carbonate, buffering agents, and lactose, as well as other common excipients used in drugs, which are solidified by application of adhesive rather than solvent. In the case of polymers for use in making devices for cell attachment and growth, polymers are selected based on the ability of the polymer to elicit the appropriate biological response from cells, for example, attachment, migration, proliferation and gene expression.

Erodible bioactive agent delivery devices are one of the simplest medical devices that can be constructed. These types of bioactive agent delivery devices can be used in an oral or implantable form depending on the desired method for delivering the specific bioactive agent. They differ in the time period over which the bioactive agent is delivered and excipients used in the device construction. Erodible bioactive agent delivery systems are constructed by dispersing the desired bioactive agent in a matrix chosen so that it dissolves or decomposes in the presence of a body fluid. Oral erodible systems, for example, begin to dissolve when they contact digestive fluids. Implantable erodible devices, for example, composed of polyester or polyamides, will slowly hydrolyze in contact with body fluid. In principle, release of the bioactive agent in both cases is controlled both by the rate at which the excipient reacts with the fluid and the rate of bioactive agent diffusion out of the device. This is true only if the surface of the device erodes in

a uniform manner and its internal structure remains unchanged by prior reaction at the surface.

- Photopolymerizable, biocompatible water-soluble polymers include polyethylene glycol tetraacrylate (Ms 18,500) which can be photopolymerized with an argon laser under biologically compatible conditions using an initiator such as triethanolamine, N-vinylpyrrolidone, and eosin Y. Similar photopolymerizable macromers having a poly(ethylene glycol) central block, extended with hydrolyzable oligomers such as oligo(d,l-lactic acid) or oligo(glycolic acid) and terminated with acrylate groups, may be used.
- Examples of biocompatible polymers with low melting temperatures include polyethyleneglycol 400 which melts at 4-8°C, PEG 600 melts at 20-25°C, and PEG 1500 which melts at 44-48°C, and stearic acid which melts at 70°C.
- Other suitable polymers can be obtained by reference to The Polymer Handbook, 3rd edition (Wiley, NY 1989), the teachings of which are incorporated herein.

- In the case of devices for delivery of bioactive agents, the material for construction of the devices is selected based on the mechanism of drug transport and the compatibility of their processing technology with the stability of the bioactive agent. A preferred material is a polyester in the polylactide/polyglycolide family. These polymers have received a great deal of attention with respect to drug delivery and tissue regeneration for a number of reasons. They have been in use for over 20 years in surgical sutures, are Food and Drug Administration (FDA)-approved and have a long and favorable clinical record. A wide range of physical properties and degradation times

can be achieved by varying the monomer ratios in lactide/glycolide copolymers: poly-L-lactic acid (PLLA) and poly-glycolic acid (PGA) exhibit a high degree of crystallinity and degrade relatively slowly, while copolymers of PLLA and PGA, PLGAs, are amorphous and rapidly degraded. Although attempts have been made to develop true surface-eroding polymer, for example, polyanhydrides, the relationship between polymer composition and device properties are very difficult to control in practice by standard fabrication techniques. These problems are avoided using the processing technology described herein.

In the case of polymers for use in making devices for cell attachment and growth, polymers are selected based on the ability of the polymer to elicit the appropriate biological response from cells, for example, attachment, migration, proliferation and gene expression. A number of suitable polymers are known, including many described above with reference to delivery of bioactive agent, for example, poly(lactic acid).

#### Binders and Polymer Concentration

The binder can be a resorbable polymer such as polylactic acid or polycaprolactone of molecular weight 50,000-200,000, in a solvent such as chloroform or a mixture of chloroform and a less-volatile solvent such as ethyl acetate to minimize warping.

The polymer concentration in the binder solution will generally be at the limit of what can be accommodated by the nozzle, both to maximize the amount of matter delivered and to minimize migration of the solvent away from the ballistic impact point of the drop, thereby maximizing the resolution of the line width. The upper limit of polymer concentration is 15% for poly-L-lactic acid

- of 100,000 MW. This concentration of polymer may in some cases be insufficient in one-pass printing; devices made with larger powders may be cohesive with this amount of polymer. The amount of matter
- 5 printed can be increased by including small latex or other particles in the printing solution. For example, polyglycolic acid (PGA) is not soluble in chloroform or ethyl acetate. Nanoparticles of PGA could be included in the printing solution
- 10 (particles up to microns in diameter can be accommodated through the nozzle) to increase the polymer content which is printed. Latexes containing 30% by weight polymer (Eudragit™ are commercially available acrylic latexes) have been
- 15 printed in existing machines without complications.

The amount of matter which is printed into the bed can also be increased by including small inorganic particles in the polymer solution, for example, bone derive apatite.

- 20 Another approach to increasing the amount of polymer printed in the bed is to print a second or more passes after the first pass has dried before moving to the next layer.

#### Construction of preforms for tissue

#### 25 engineering.

- Regeneration of native tissue structures may occur by stimulation of growth of neighboring, healthy tissue (e.g., healing a defect in bone) or may require transplantation of cells from another
- 30 site, using either the patient's own tissue or that of a tissue-matched donor (e.g., growth of a new cartilage structure for plastic surgery, replacement of liver). In either case, a device which serves as a scaffold or template to aid the
- 35 growth of the new tissue is almost always necessary. The device may serve many functions,

- including: (1) as an immobilization site for transplanted cells, (2) forming a protective space to prevent soft tissue prolapse into the wound bed and allow healing with differentiated tissue, (3) directing migration or growth of cells via surface properties of the device, and (4) directing migration or growth of cells via release of soluble molecules such as growth factors, hormones, or cytokines.

10     Means for Altering Texture of Device Features

- A "wall", for example, a feature 100 microns thick by 1 cm x 1 cm, will exhibit different textures if it is built by printing a single line layer after layer up through the depth of the bed, as compared to printing a sheet of contiguous lines within one layer. The wall built up by printing a line layer after layer will have texture on both sides (some of the powder will adhere), and that texture will be identical on each side. In contrast, a sheet printed using contiguous lines within the same layer will in most cases have different textures on each side. The "bottom" will have a texture influenced by incomplete assimilation of the powder into the bulk of the polymer wall. The "top" can be smooth, because more binder is inherently trapped in the top of the printed line, covering up the particles. However, at low polymer concentrations in the printed binder, the top of the "sheet" can also exhibit significant texture since the binder is less viscous and can penetrate into the powder more easily.

- The texture in a sheet is influenced both by the binder concentration in the powder and by the spacing between contiguous lines. For example, a 15% PCL solution in chloroform printed into PCL powder with 75-100 micron powder size using a

- printing speed of  
4-12 cm/s will form a smooth layer if printed at a  
spacing of 25 microns but will form a highly  
textured surface if printed at a spacing of 75  
5 microns.

These effects of texture can be beneficial in  
designing devices to get optimal tissue  
regeneration rates. A single channel of square  
cross-section can have smooth surfaces on one or  
10 two sides and textured surfaces on the other.  
Smooth surfaces can allow rapid cell migration,  
while textured surfaces can provide a site for  
cells to differentiate.

#### Formation of composite Devices

- 15 Composite devices can be made by combining  
inorganic and organic components. In particular,  
it may be desired to increase the amount of polymer  
in the device above that which can be obtained by  
one-pass printing of a polymer solution into an  
20 inorganic powder bed, for example, by adding a  
polymer latex to the printing solution. Another  
method is to mix a polymer powder with an inorganic  
powder. Still another method is to spread only  
polymer powder in the bed, and print a dispersion  
25 of inorganic particles (up to 30 vol%) in a solvent  
which will bind the polymer powder together. An  
example of this is to print a solution of apatite  
particles in chloroform onto a PLA powder bed.  
Alternatively one can include a polymer binder with  
30 an inorganic dispersion, for example by adding 30%  
by volume particles to a 5% by weight solution of  
PLA in chloroform. In the extreme, the bed could  
contain no material at all; both the inorganic and  
organic material could be printed through the  
35 nozzle.

#### Binders for Delivery of Bioactive Agent

The binder can be a solvent for the polymer



and/or bioactive agent or an adhesive which binds the polymer particles. Solvents for most of the thermoplastic polymers are known, for example, methylene chloride or other organic solvents.

- 5 Organic and aqueous solvents for the protein and polysaccharide polymers are also known, although an aqueous solution is preferred if denaturation of the protein is to be avoided. In some cases, however, binding is best achieved by denaturation  
10 of the protein.

The binder can be the same material as is used in conventional powder processing methods or may be designed to ultimately yield the same binder through chemical or physical changes that take  
15 place in the powder bed after printing, for example, as a result of heating, photopolymerization, or catalysis.

- The selection of the solvent for the bioactive agent depends on the desired mode of release. In  
20 the case of an erodible device, the solvent is selected to either dissolve the matrix or is selected to contain a second polymer which is deposited along with the drug. In the first case, the printed droplet locally dissolves the polymer  
25 powder and begins to evaporate. The drug is effectively deposited in the polymer powder after evaporation since the dissolved polymer is deposited along with the drug. The case where both the drug and a polymer are dissolved in the printed  
30 solution is useful in cases where the powder layer is not soluble in the solvent. In this case, binding is achieved by deposition of the drug polymer composite at the necks between the powder particles so that they are effectively bound  
35 together.

Aggressive solvents tend to nearly dissolve the particles and reprecipitate dense polymer upon

drying. The time for drying is primarily determined by the vapor pressure of the solvent. There is a range from one extreme over which the polymer is very soluble, for example, 30 weight percent solubility, which allows the polymer to dissolve very quickly, during the time required to print one layer, as compared with lower solubilities. The degree to which the particles are attacked depends on the particle size and the solubility of the polymer in the solvent. Fine powder is more completely dissolved than powder with larger particle size.

Bioactive agents which can be incorporated.

There are essentially no limitations on the bioactive agents that can be incorporated into the devices, although those materials which can be processed into particles using spray drying, atomization, grinding, or other standard methodology, or those materials which can be formed into emulsifications, microparticles, liposomes, or other small particles, and which remain stable chemically and retain biological activity in a polymeric matrix, are preferred. Bioactive agents also include compounds having principally a structural role, for example, hydroxyapatite crystals in a matrix for bone regeneration. The particles may have a size of greater than or less than the particle size of the polymer particles used to make the matrix.

Examples generally include proteins and peptides, nucleic acids, polysaccharides, nucleic acids, lipids, and non-protein organic and inorganic compounds, referred to herein as "bioactive agents" unless specifically stated otherwise. These materials have biological effects including, but not limited to, anti-inflammatories, antimicrobials, anti-cancer, antivirals, hormones,

- antioxidants, channel blockers, and vaccines. It is also possible to incorporate materials not exerting a biological effect such as air, radiopaque materials such as barium, or other imaging agents.

Patterns for incorporation of Bioactive Agent

- There are two principle methods for incorporation of bioactive agents: as a dispersion within a polymeric matrix and as discrete units within a discrete polymeric matrix. In the first case, the bioactive agent is preferably applied in the polymer particle binder; in the second, the bioactive agent is applied in a non-solvent for the polymer particles.

- In the case of SLA, bioactive material to be incorporated is dispersed into the liquid matrix material; in all other cases, bioactive material to be incorporated can be mixed with the particles, although this can result in a significant waste of the material in the case of SLS and 3DP; in these cases it is preferable to incorporate the bioactive material into the solvent or binder.

- For example, the devices can be composed of particles of bioactive agent dispersed or embedded in a matrix of degradable polymer, such as PLA, PGA, and their copolymers (PLGAs). Implantation of the device is followed by slow hydrolysis and erosion of the polymer matrix. The release rate of bioactive agent is determined by the erosion rate of the polymer rather than just diffusion. Thus, the drug release rate can be controlled by the distribution of the drug throughout the matrix or by variation of the polymer microstructure so that the erosion rate varies with the position in the device. A drug concentration profile that is periodic with position away from the device surface will, for example, yield a drug release rate that

is periodic in time as the polymer is eroded. The same effect could also be achieved by periodic variation in polymer composition or porosity.

- The devices having these release profiles can be constructed as follows. The devices formed using 3DP consist of horizontal layers, or planes, of polymer and/or bioactive agent, arranged in a vertical plane to create a device. Composition gradients are created by applying a different amount of bioactive agent, or different combinations of bioactive agent, in different layers or within different regions of one or more layers. For example, in a device degrading or releasing from the vertical ends, layer one could consist entirely of polymer. Layer two could have a region of bioactive agent with a concentration of 1 mM; layer three a concentration of 1.2 mM; layer four a concentration of 1.4 mM, until the calculated center of the device is reached, at which point the concentration would begin to decrease. Alternatively, for a device degrading or releasing from the vertical sides of the device, the concentration could be formed radially; i.e., the concentration would increase from the outside of the device inwardly, or vice versa, for constant release over a concentration gradient.
- Alternatively, one could have a discontinuous concentration gradient, for example, where the device is in the form of a cylinder, where, from the outside inward, the outside vertical wall of the cylinder is polymer, the next layer(s) is bioactive agent alone or in combination with polymer, the next layer(s) is polymer, and the next layer(s) is bioactive agent, so that there is a pulsed release as the device degrades. As discussed above, structural elements can be incorporated into the polymeric matrix to insure

the mechanical integrity of the erodible devices.

Incorporation of Structural Elements

- Practical application of erodible devices is limited by the mechanical integrity of the device during the course of erosion. Real erodible devices do not decompose by simple surface limited reactions. Rather, the surface and bulk microstructure evolve during the course of erosion and alter the rate at which the drug is delivered.
- 10 For example, oral erodible devices pit and bread apart, which modifies the surface area exposed to the fluid and changes the rate at which drug is released. Resorbable polymer devices swell before hydrolysis which also causes nonlinear release of
- 15 the drug.

- Structural elements made using the same or different polymeric particles can be designed within the device to provide physical structural support during degradation so as to avoid many of the problems associated with erodible devices. 3DP is used to create structural elements within the device formed by the solidification of the polymer particles, for example, by deposition of areas or regions of a different polymeric material, such as
- 20 regions of a non-degradable polymer within regions of a degradable polymer.

Control of Porosity in Devices.

- Porosity in 3D printed devices may be created either at the level of the feature size (10-20 microns and greater) or at a sub-feature size level. At the level of the feature size, porosity is controlled by where the features are placed, and thus pore size and shape can vary in three dimensions.
- 35 Porosity at a subfeature size level can be created in a variety of ways.

- (1) Printing of a polymer solution onto a bed

of particles which are not soluble in the polymer and which can be subsequently leached by a non-solvent for the polymer. In this case, the polymer which forms the device is printed onto a bed of particles such as salt, sugar, or polyethylene oxide. After the printing process is complete, the device is removed from the powder bed and placed in a nonsolvent for the polymer which will dissolve the particles. For example, polylactic acid in chloroform could be printed onto a bed of sugar particles, and the sugar can subsequently be leached with water.

(2) Printing a polymer solution onto a bed of particles which are partially soluble in the printed solvent. An example is printing a polylactic acid solution onto a bed of polyethylene oxide particles. This procedure may allow interpenetration of PEO into the surface of the PLA and improve surface properties of the final device. Following printing, the PEO can be leached with water.

(3) Printing a polymer solution onto a heated bed of polymer. An example is printing polylactic acid in chloroform onto a bed of PLA particles heated to 100°C. The boiling point of chloroform is 60°C, and it will thus boil on hitting the particle bed, causing a foam to form.

(4) Printing a polymer solution onto a bed containing a foaming agent.

(5) Printing with less aggressive solvents which have only a small solubility for the powder. Only a small amount of polymer is deposited at the necks between the particles leaving much of the original porosity in the powder bed. For example, PCL is only slightly soluble in acetone and acetone has a relatively high vapor pressure. Very little polymer is, therefore, dissolved before the solvent

dries. Thus, the necks formed between the particles are small and the porosity of the resulting component is much like that of the original powder bed.

5     Devices having modified surface properties.

Modifying surface properties in select regions of the device is also important and can be accomplished by printing a solution containing surface-active agents into the regions or lines in  
10    between where the binder is printed. As used herein, a "surface-active agent" may be an agent which promotes cell adhesion, such as an RGD peptide, or a material which inhibits cell adhesion, such as a surfactant, for example,  
15    polyethylene glycol or a Pluronic™ (polypropylene oxid-polyethylene oxide block copolymers). The surface-active agent should in general be contained in a solvent immiscible with the solvent used to print the binder.

20    For example, it may be desirable to incorporate adhesion peptides such as the RGD adhesion peptide into certain channels (e.g., those for blood vessel ingrowth). An adhesion peptide, such as the peptide having a hydrophobic tail  
25    marketed by Telios (LaHoya, California) as Peptide™, can be dissolved in water and printed into the "voids" using a second set of printing nozzles. Adding water, a relatively non-volatile solvent, can alter the kinetics of solvent removal  
30    from regions printed with binder. For example, adding water can slow solvent removal by occluding the surface area for evaporation, and can help decrease warpage. On contact with the polymer surface, the peptide will adsorb out of solution  
35    onto the polymer surface.

The surface can also be modified to prevent cellular adhesion. This may be desirable to

prevent excessive soft connective tissue ingrowth into the device from the surrounding tissue, and can be accomplished, for example, by printing an aqueous solution of a pluronic™ (BASF) or poloxamer™ in the voids. The hydrophobic block of such copolymers will adsorb to the surface of the channels, with the hydrophilic block extending into the aqueous phase. Surfaces with adsorbed pluronics™ resist adsorption of proteins and other biological macromolecules. Other adhesion-preventing materials are described in Lee, J.H., J. Kopecek, et al., "Protein-resistant surfaces prepared by PEO-containing block copolymer surfactants." J. Biomed. Mat. Res., 23:351-368 (1989), the teachings of which are hereby incorporated by reference.

Printing the device with surface active agents while the "walls" of the device are still "wet" with organic solvent (such as chloroform) can enhance the adsorption of the adhesion-preventing material to the walls and can even allow the hydrophobic block to become blended into the surface, enhancing the stability of the resulting surface modification.

For the applications described above, as well as for other applications in tissue regeneration and delivery of bioactive agents which can be envisioned, 3DP offers at least three advantages over current technologies for processing biodegradable polymers: (1) tailored macroscopic shapes, (2) well-defined microstructure, which may include bimodal pore size distribution and directionally oriented pores and channels, and (3) incorporation of growth factors during manufacture in order to provide controlled release of factors at specific sites.



Devices for Regeneration of Specific Tissues

As used herein, "tissue" includes both soft tissues such as parenchymal tissue (liver, pancreas, intestine, etc.), blood vessels, skin, and connective tissues such as cartilage and bone.

- Although matrix construction varies with each tissue type, the methods used for construction will typically be the same, optimized to create appropriate shapes and pore sizes. In general, interconnected pores or channels will extend from the exterior throughout the interior, typically between 0.15 and 0.5 mm in diameter, which are separated by walls approximately 30 to 100 microns thick, which are either solid or porous with an average pore size of approximately 5 to 40 microns.

- Ideally, devices used for tissue regeneration will have a specific macroscopic shape which can be fashioned to the specific needs of a patient. For example, in mandibular replacement a missing piece of the jaw bone on one side of the patient will be fabricated to exactly match existing bone on the undamaged side by inputting an MRI image of the existing bone into the CAD program which fabricates the device. Further, the devices will ideally have a specific tailored microstructure of interconnected pores and channels for tissue ingrowth where the pores and channels are of precisely defined size, shape, surface chemistry and position within three dimensions. For example, in the case of bone ingrowth, there may be large longitudinal channels for ingrowth of bone and blood vessels from the adjoining bone and smaller transverse channels for ingrowth of blood vessels from the periosteal tissue.

- The design of a bone regeneration device is described below in Example 1. Similar techniques for creating tailored microstructures with specific

surface chemistries and textures can be applied to almost any type of tissue. Microstructures tailored to bone involve a composite of inorganic particulates and organic material in the final device, and are the most general. Matrices for regenerating other tissues, such as liver and cartilage, can be fabricated in a similar fashion using either inorganic powder or polymer powder in the bed. For microstructures tailored to soft tissues it is undesirable to have an inorganic powder as a component of the final device. However, printing a solution of a polymer such as PLA in chloroform onto an inorganic powder bed or onto a bed of mixed polymer/inorganic is a technique for creating increased porosity in the final device if a water-soluble inorganic powder such as sodium chloride is used.

For microstructures tailored to bone, inorganic powders in the final device increase the strength of the device and provide a source of minerals for the regenerating tissue. The strength requirements of soft tissues such as liver are substantially less than for bone, so greater void fractions in the final devices can be tolerated.

Although these devices can be created by any of the SFF techniques, the preferred method is 3DP. In one approach, an inorganic powder is spread in the bed. This powder will generally be some form of calcium phosphate or hydroxyapatite and can be derived from natural sources (i.e., isolated from animal bones) or synthetically created powder. If the powder is isolated from bone (for example, by grinding bone in a Glenn Mills Milling machine), it may not be strictly inorganic but may contain natural proteins and other biological macromolecules. The powder is preferably resorbable or biodegradable. The powder size

controls the resolution of the wall thickness and the layer thickness. Powders less than 40 microns in diameter are preferred in order to obtain resolutions of less than 100 microns. Resolution is generally at least twice the dimension of the powder size. Very fine powders, typically less than one micron in diameter, may be spread into the bed as a solution which is then allowed to dry, or such powders can be formed into thin, generally between 100 and 200 micron thick, coherent, porous sheets by non-specific interactions in a separate step outside the 3DP machine, and the resulting sheets can be laid in the bed as each layer is built up as an alternative to the normal rolling and spreading operation. Bone derived apatite is an example of an inorganic powder which can be processed in this manner. Bone derived apatite has particles of average dimensions  $0.003 \times 0.009 \times 0.04$  microns.

After a first layer of powder is spread or placed in the bed of the SFF device, a binder is printed at those locations where it is desired to have walls. The places where no binder is printed become channels or voids when the powder is removed at the end of the process. For long-bone fracture repair devices, a preferred design is to have straight channels of approximately 60 to 300 microns in diameter with approximately 60 to 150 micron walls running the length of the device end-to-end to allow the neighboring bone to grow into the device, and transverse channels of approximately 60 to 100 microns in diameter which will allow ingrowth of blood vessels from the periosteal region. Although the transverse channels need not be as numerous as the longitudinal channels from the perspective of the need for blood vessels to grow in, the overall void

fraction of the device should remain at greater than 80%. It may be desirable to have transverse walls as thin as 100 microns. The outermost layer may also be designed to prevent excessive tissue ingrowth from the periosteal region, by limiting the number of internal channels which are accessible.

The methods and devices described herein will be further understood by reference to the construction of a cylindrical matrix for delivery of bioactive agent and bone tissue preform below.

Example 1: Construction of a cylindrical matrix having bioactive agent dispersed throughout the matrix.

The macrostructure and porosity of the device is designed and manipulated by controlling printing parameters. A layer of fine polymer powder having a particle size less than 20  $\mu\text{m}$  is spread on a solid support which can be moved away from the printhead as layers are built. The powder is selectively bound by ink-jet printing a solvent or mixture of solvents which dissolves the polymer (e.g., methylene chloride for ethylene vinyl acetate, or chloroform for biodegradable polyesters). This process is repeated for subsequent layers to build up the cylinder: the second layer is printed directly on top of the first, and so on until the cylinder is completed.

To design a constant rate release matrix, the bioactive agent is dissolved or dispersed (e.g., micellar) form in the polymer forming the matrix, so that the bioactive agent is dispersed evenly through the matrix. As in the device described above, the printing process is then continued layer by layer until the desired shape is obtained.

**Example 2:** Construction of a cylindrical matrix having bioactive agent located in discrete regions within the matrix.

Devices for pulsed release of bioactive agent can be obtained by constructing bioactive agent-rich regions within the polymer matrix. In this case, multiple printheads are used to deposit solvent containing bioactive agent in selected regions of the powder bed. The remaining volume of the desired device is bound with pure solvent deposited by a separate printhead. The printing process is then repeated layer by layer, resulting in, for example, a cylindrical device including a cylindrical annulus region which is enriched in a drug. Drug therapies could be devised with graded delivery of multiple drugs simply by adding multiple printheads.

**Example 3:** Construction of a cylindrical matrix having structural elements within the matrix.

A device which can maintain structural integrity during erosion is shown in Figures 1A and 1B. The basic design of the device is to surround regions of resorbable polymer containing bioactive agent with a matrix of either nonresorbing or slowly resorbing polymer. This matrix maintains the structural integrity of the resorbing material. The width of the device is chosen so that it is less than five millimeters, so that it can be implanted by a trocar. The regions containing bioactive agent follow the axis of the device and are connected to one or both ends of the device. Thus, resorption of the bioactive agent containing regions will proceed axially from the ends. The width of the bioactive agent containing regions is chosen to be much smaller than the width of the device so that true one-dimensional diffusion will exist along the axis of the device. This feature considerably simplifies the analysis required to

determine the proper distribution of bioactive agent along the axis of the device.

The materials needed to construct the device in Figures 1A and 1B can be chosen from those currently used in implantable erosive drug delivery devices. This device is constructed by spreading PGA-PLA copolymer powder. The axial filaments, which contain the bioactive agent, are bonded together by printing bioactive agent-chloroform solutions. Drug composition profiles can be created by either printing different bioactive agent solutions into different regions of the filaments or repeated printing of a given solution into regions where high bioactive agent concentration is desired. The matrix around the bioactive agent containing filaments is created by printing solutions of polycaprolactone (PCL) in chloroform. PCL resorbs much slower than the PGA-PLA copolymer powder. Upon drying each layer, the PCL will bind and coat the PGA-PLA powder and dramatically reduce its resorption rate.

Similar fabrication approaches can be used to create oral drug delivery devices. Oral drug delivery devices can be made by printing bioactive agent and digestible polymer solutions into powder composed of acceptable excipient material. Complex composition profiles of the bioactive agent and polymer can be built into the device so that the bioactive agent release rate can be controlled. Polymer-rich walls of a cellular structure could, for example, be built within the device so that their resorption rate controls the release of the bioactive agent held within the cells. The polymer cells simultaneously isolate the bioactive agent from digestive fluids which may inactivate the bioactive agent.

**Example 4: Construction of a porous matrix for bone regeneration.**

Three degrees of hierarchy in control of device structure are important, as shown in Figures 2A, 2B, and 2C. At the highest level, gross macroscopic shape is important and formation of complex, three-dimensional shapes is essential for many applications, such as replacement of cartilage and bone. The ability to create specific porous shapes in response to individual patient parameters is a goal not yet realized by current processing techniques. At a second level, control of pore or channel size and orientation on the scale of 50 microns to 1 mm is important. For example, in a bone replacement device, it may be advantageous to have a series of large (approximately 200-500 micron) channels oriented anisotropically along the length of the device to encourage rapid growth of large blood vessels from the anastomoses with the native bone, and have smaller pores leading out of these channels for cell growth. It may also be desired to orient these pores in a graded fashion, with more pores on the interior of the device (facing bone) than on the exterior so that prolapse of soft tissue into the bone will be minimized. Another important feature to control at this level of resolution is distribution of soluble factors which might be released from the device to influence cell behavior. For example, in the case of bone, one might want to release bone morphogenic proteins along the side of the device which faces the bone, and release factors which inhibit soft tissue growth (e.g., decorin) along the side which faces soft tissue. Finally, at a third level, the "walls" of the device may themselves be porous on a scale of 1-10 microns. The porosity at this level

is uniform throughout the wall.

This example describes the production of a rectangular device 2 cm x 1 cm x 1 cm, where it is desired to have the bone grow in the direction  
5 which is 2 cm long, and all other outer surfaces will be in contact with soft tissue. This can be built by printing:

1st layer:

Lines 100 microns wide spaced 300 microns  
10 center-to-center along the length of the 2 cm axis (each line is 200 microns in depth), for a total of 30 lines.

Triplets of 100 micron wide lines (i.e., three lines printed side by side) with 100 micron spacing  
15 in between printed along the 1-cm axis, for a total of 25 triplets, to decrease the number of channels accessible from the outside.

2nd layer:

Lines 100 microns wide spaced 300 microns  
20 center-to-center along the length of the 2-cm axis; these lines are 200 microns in depth and placed directly above the lines in the previous layer. The spaces between the lines will form the longitudinal channels.

25 3rd layer:

Lines 100 microns wide with 100 micron spacing printed along the 1 cm axis with 100 micron spacing in between; a 200 micron depth in all layers is assumed from here on; lines are printed on top of  
30 each of the outside lines in each triplet in the layer below. In this layer, the only binder printed along the 2-cm axis is printed on the 2 outermost lines; in these lines, binder is printed on top of regions where the transverse triplets  
35 intersect the outermost line; this is to prevent excessive tissue ingrowth from the side directions.

4th-(n-2)th layer: Same as layer 2.



5th-(n-1)th layer: Same as layer 3.

nth layer: Same as layer 1.

A device 1 cm thick would have approximately 50 layers.

- 5 An alternative to the embodiment described above is to rotate the axes in any direction in the bed so the longitudinal channels (2-cm direction), for example, are built up through the depth of the bed. This approach may be particularly desirable
- 10 due to the effect of position in the bed on the texture an exposed surface assumes, as discussed above.

- The device described above can be modified to encompass more complex architectural features and
- 15 macroscopic shapes by varying the printing instructions. For example, some of the lines in the second layer could be single, some could be pairs, some could be triplets. A pair is two lines printed contiguous to each other within a single
- 20 layer. A triplet is three lines printed contiguous to each other within a single layer.

**Example 5: Construction of Composite Devices.**

- In a different embodiment, an exogenously fabricated polymer device is incorporated within
- 25 the 3DP fabricated device. Examples of exogenously fabricated devices include strips of a microporous membrane which are incorporated into the center of the device to enhance angiogenesis by the "architecture-driven mode" described by Jim Brauker
- 30 & coworkers (Baxter Corp., Round Lake, Ill.). Architecture-driven angiogenesis refers to the appearance of stable blood vessel ingrowth next to an implanted membrane device as a result of the microstructure of the membrane independent of
- 35 membrane material as long as the material is nontoxic.

Microporous membranes with fibrous

architectures and pores in the range of between approximately 5 to 8 microns are associated with vascularized fibrous capsules. In contrast, nonporous membranes or membranes with larger pores or with sheet-like rather than fibrous architectures are associated with avascular fibrous capsules. Architecture-driven vascularity is believed to be brought about by cytokines secreted by macrophages which infiltrate the pores of the microporous membrane. Microporous membranes can therefore be used as angiogenesis factors to attract blood vessel ingrowth into a laminated macroporous device (two macroporous membranes glued onto the outer surfaces of the microporous "angiogenic" membrane).

For a bone regeneration device, the microporous membrane (200 microns thick is standard) can either replace an entire layer or a thin (0.3 cm x 2 cm, for the device described above) strip can be placed in the center of a layer with normal powder in the remainder of the layer. Another method for generating this type of microstructure is by "spreading" short small-diameter (less than about three micron) fibers; however, this is technically more difficult.

Modifications and variations of the method and compositions described herein will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.

We claim:

1. A method for making medical devices comprising forming a polymeric matrix using a solid free-form fabrication method to form sequential layers of polymeric material.
2. The method of claim 1 wherein the method is ballistic particle manufacturing or fusion deposition modeling and polymeric material is applied to a platform in layers to form a polymeric device.
3. The method of claim 1 wherein the method is three dimensional printing, comprising preparing a dispersion of particles formed of a biocompatible polymer on a platform; and applying a binder for the polymeric particle to the dispersion of polymer particles to form a pattern of solidified polymer.
4. The method of claim 1 wherein the method is selective laser sintering comprising applying polymeric particles to a platform and fusing selected area of the polymeric particles with a laser.
5. The method of claim 1 wherein the method is stereo-lithography comprising photopolymerizing selected areas of a bath of photopolymerizable prepolymer or monomers.
6. The method of claim 1 further comprising adding to the polymeric material a bioactive agent.
7. The method of claim 6 wherein the bioactive agent is added to polymeric particles used to form the polymer layers.
8. The method of claim 6 wherein the bioactive agent is added to a solvent or binder for polymeric particles used to form the polymer layers.
9. The method of claim 8 wherein the solvent for the bioactive agent is not a solvent for the

polymer, wherein three dimensional printing is used to form discrete regions of bioactive agent within a polymeric matrix.

10. The method of claim 6 wherein the bioactive agent is added to the polymer particles in a solvent for the polymer and the bioactive agent is applied to the polymer particles at the same time as the polymer is dissolved and resolidified.

11. The method of claim 3 wherein the polymer particles have a diameter of at least approximately ten microns or less.

12. The method of claim 1 wherein the polymer is a biodegradable polymer.

13. The method of claim 6 wherein the polymer is a non-degradable polymer and forms a porous matrix through which bioactive agent can diffuse out of the device.

14. The method of claim 6 wherein the bioactive agent is present in the device in different concentrations.

15. The method of claim 14 wherein the bioactive agent forms a concentration gradient.

16. The method of claim 6 wherein the bioactive agent is incorporated into the polymeric device so as to result in pulsed release.

17. The method of claim 1 further comprising creating porous spaces within the polymeric device which allow cell attachment and growth within the porous spaces.

18. The method of claim 17 wherein the method is three dimensional printing, comprising

a) spreading a first dispersion of a biocompatible polymer or composite powder onto a bed,

b) printing a layer comprising a second dispersion of biocompatible polymer or composite

powder in a solvent which binds the first biocompatible polymer or composite powder to the second biocompatible polymer or composite powder at locations where it is desired to have walls, and

c) repeating step b until the desired matrix is made.

19. The method of claim 18 wherein the powder is a resorbable powder selected from the group consisting of calcium phosphate, hydroxyapatite, and calcium carbonate and the device is for bone regeneration or repair.

20. The method of claim 17 wherein the powder size is less than 40 microns in diameter.

21. The method of claim 17 wherein the device includes walls which are less than 100 microns thick.

22. The method of claim 1 further comprising adding a biodegradable latex to the polymer.

23. The method of claim 1 further comprising printing a solution containing surface-active agents into the regions or lines of the powder bed in between where the binder is printed.

24. The method of claim 1 further comprising modifying the surface of the polymer with a surface active agent which prevents adhesion of cells.

25. The method of claim 1, further comprising incorporating an exogenously fabricated device into the matrix by printing layers of binder around the exogenously fabricated device.

26. The method of claim 1 further comprising incorporating a non-biodegradable material into the device to form structural elements maintaining the integrity of the device when formed of a biodegradable material.

27. A device formed by the method of any of claims 1 to 26.

28. A method for delivering a bioactive agent

comprising providing at the site where delivery is desired a device formed by the method of any of claims 1 to 16 or 23 to 26.

29. A method for regenerating or repairing a tissue comprising providing at the site where regeneration or repair is desired a device formed by the method of any of claims 1 to 26.

27. A medical device formed using a solid free-form fabrication method to form sequential layers of polymeric material.

FIG. 1a





FIG. 1b



2/2




Figure 2

SUBSTITUTE SHEET (RULE 20)

BEST AVAILABLE COPY



# INTERNATIONAL SEARCH REPORT

Intern. Pat. Application No.  
PCT/US 94/11893

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/00 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 046 513 (JOHNSON) 6 September 1977 -----	
A	US,A,4 520 821 (SCHMIDT ET AL) 4 June 1985 cited in the application -----	
A	US,A,4 060 081 (YANNAS ET AL.) 29 November 1977 cited in the application -----	
A	US,A,4 485 097 (BELL) 27 November 1984 cited in the application -----	
A	EP,A,0 431 924 (M.I.T.) 12 June 1991 cited in the application -----	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

23 February 1995

Date of mailing of the international search report

13.03.95

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
T'd. (+31-70) 340-2040, Tlx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Klaver, T

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No.

PCT/US 94/11893

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US-A-4046513	06-09-77	AT-B-	352905	10-10-79
		AU-B-	512788	30-10-80
		AU-A-	2661377	04-01-79
		BE-A-	856280	17-10-77
		CA-A-	1101319	19-05-81
		CH-A-	637483	29-07-83
		DE-A, C	2729333	09-02-78
		FR-A, B	2356941	27-01-78
		JP-C-	1081409	29-01-82
		JP-A-	53003885	13-01-78
		JP-B-	56018904	02-05-81
		LU-A-	77655	10-10-77
		NL-A-	7707274	03-01-78
		SE-A-	7707539	31-12-77
-----				
US-A-4520821	04-06-85	NONE		
-----				
US-A-4060081	29-11-77	CA-A-	1071814	19-02-80
		DE-A, C	2631909	10-02-77
		FR-A, B	2332863	24-06-77
		GB-A-	1518748	26-07-78
		JP-C-	1136044	28-02-83
		JP-A-	52038796	25-03-77
		JP-B-	57027834	12-06-82
-----				
US-A-4485097	27-11-84	US-A-	4485096	27-11-84
		EP-A, B	0110966	20-06-84
		WO-A-	8304177	08-12-83
-----				
EP-A-0431924	12-06-91	US-A-	5204055	20-04-93
		CA-A, C	2031562	09-06-91
		JP-A-	6218712	09-08-94
		US-A-	5340656	23-08-94
		US-A-	5387380	07-02-95
-----				